← back to search

Carl de Moor

Biogen (United States) · US
Area of research
Pathology and Forensic Medicine · Physiology
Research interest
Research interests include Multiple Sclerosis Research Studies, Smoking Behavior and Cessation, Obesity, Physical Activity, Diet, and Cancer survivorship and care.
h-index
43
citations
7,269
works
184
NIH funding
primary concept
email

Recent publications

Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis
Neurology 2024cited by 36position: middledoi
Generating real‐world evidence in Alzheimer's disease: Considerations for establishing a core dataset
Alzheimer s & Dementia 2024cited by 18position: middledoi
Visualizing the target estimand in comparative effectiveness studies with multiple treatments.
2024cited by 0position: contributordoi
Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial
Multiple Sclerosis Journal - Experimental Translational and Clinical 2023cited by 11position: middledoi
Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An instrumental variable meta‐analysis
Alzheimer s & Dementia 2022cited by 22position: middledoi
No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS
Multiple Sclerosis and Related Disorders 2022cited by 20position: middledoi
Digital Devices for Assessing Motor Functions in Mobility-Impaired and Healthy Populations: Systematic Literature Review.
2022cited by 16position: contributordoi
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
CNS Drugs 2021cited by 121position: lastdoi
Serum neurofilament light-chain (sNfL) levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis (RRMS) patients in the CombiRx trial (2410)
Neurology 2021cited by 1position: middledoi
Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)
Frontiers in Neurology 2020cited by 90position: middledoi
Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling
Multiple Sclerosis Journal 2019cited by 27position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Elizabeth Fisher · Biogen (United States)5 papers (2020–2024)Richard A. Rudick · Norwalk Hospital4 papers (2020–2024)Carol M. Singh · Dayanand Medical College & Hospital3 papers (2021–2024)Fabio Pellegrini · Biogen (United States)3 papers (2019–2024)Bernd C. Kieseier · Novartis (Switzerland)3 papers (2019–2024) · 3 papers (2021–2023)Jerry S. Wolinsky · The University of Texas Health Science Center2 papers (2021–2023)Ivana Rubino · University of Lausanne2 papers (2022–2024) · 2 papers (2022–2024)Henry F. McFarland · Virginia Commonwealth University2 papers (2021–2023)Lauren Krupp · NYU Langone Health2 papers (2020–2022)Arman Altincatal · Sanofi (United States)2 papers (2021–2024)Fred Lublin · Icahn School of Medicine at Mount Sinai2 papers (2021–2023)Xavier Montalbán · Fundació ACE2 papers (2020–2024)Gary Cutter · Epilepsy Foundation2 papers (2021–2023)James R. Williams · University of Salford2 papers (2020–2022)Steven Jacobson · National Institute of Allergy and Infectious Diseases2 papers (2021–2023)Changyu Shen · Biogen (United States)2 papers (2022–2024)Robert T. Naismith · University of Iowa2 papers (2020–2022)Lana Zhovtis Ryerson · Hackensack Meridian Health1 papers (2022–2022)